Novo Nordisk’s CagriSema Hits Mark, But Misses Target In Obesity

Efficacy for the drug came in below investors’ expectations for beating Lilly’s Zepbound, while analysts said a lower percentage of people remaining on the highest dose suggested tolerability issues.